Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | MAP2 | P11137 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAT2A | P31153 | 2/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388357 | 0.86 | ALPL (0.45) | PTGS2ALOX5KDM4EHPGDMAPK1 | |
| SCHEMBL6594963 | 0.82 | PTGS2 (0.57) | PTGS2MAP2MAPTALOX5HRH4 | |
| SCHEMBL6994667 | 0.74 | HRH4 (0.64) | PTGS2HRH4HRH3KDM4EMEN1 | |
| SCHEMBL6384274 | 0.74 | PDE1A (0.51) | PTGS2MAPTKDM4ELMNAHPGD | |
| SCHEMBL10857861 | 0.73 | PTGS2 (0.49) | PTGS2MAPTHRH4HRH3KDM4E | |
| SCHEMBL3099150 | 0.72 | HPGD (0.50) | PTGS2MAPTKDM4EHPGDMAPK1 | |
| SCHEMBL6233791 | 0.71 | NR4A2 (0.52) | GPR17 | |
| SCHEMBL25209836 | 0.69 | LMNA (0.49) | KDM4EMEN1LMNACYP2C9HPGD | |
| SCHEMBL25199951 | 0.68 | LMNA (0.48) | MDM2KDM4EMEN1LMNACYP2C9 | |
| SCHEMBL25200779 | 0.68 | KDM4E (0.45) | MDM2KDM4EMEN1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0792273-B1 | BICYCLIC OXAZINE AND THIAZINE OXAZOLIDINONE ANTIBACTERIALS | UPJOHN CO (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1325003-B1 | 7-CHLORO-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINO 4,5-B|QUINOLINE-1,10-DIONE AND THE USE THEREOF FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1325002-B1 | 1,2,5,10-TETRAHYDROPYRIDAZINO¬4,5-B|QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1244660-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050227977-A1 | Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | US | disclosed |
| EP-1577311-A1 | Salts of a pyridazino aquinoline derivative and use for the treatment of pain | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| US-6946463-B2 | 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain | ASTRAZENECA AB (SE) | 2005-09-20 | — | — | US | disclosed |
| US-6943165-B2 | Compound and method for the treatment of pain | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6933297-B2 | 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain | ASTRAZENECA AB (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20050124622-A1 | Compounds and methods for the treatment of pain | BROWN DEAN G (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2002026738-A1 | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026740-A1 | 7-CHLORO-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-B]QUINOLINE-1,10-DIONE AND THE USE THEREOF FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026741-A1 | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001047925-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047923-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047924-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047926-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047523-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047524-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047927-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227977-A1 | Substituted 1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione compounds and methods for the treatment of pain | QDPR, OPRK1, OPRM1 | PTGS2 308/4885MAP2 1369/4885MAPT 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.